Efferon to Seek FDA Approval for Pediatric Blood Purification Device
Efferon, picked for TechCrunch Disrupt 2026's Startup Battlefield 200, is preparing an FDA filing for Efferon NEO and targets $2 million in annualized revenue by end of 2026.
Efferon, a startup developing blood purification technology, said it is preparing to file for FDA approval of its pediatric device Efferon NEO. The announcement comes as the company was selected as one of TechCrunch Disrupt 2026's Startup Battlefield 200, according to TechCrunch.
The company also said it is on track to hit $2 million in annualized revenue by the end of 2026.
Efferon NEO received a CE mark in April, making it the first multimodal blood purification device specifically engineered for pediatric sepsis. The device is used in intensive care units across 30 countries, including hospitals in Europe, Saudi Arabia and Thailand.
The technology behind Efferon was originally developed by scientists at Moscow State University, including co-founder Ivan Bessonov. Earlier this year, Dima Romashin joined as CEO to help commercialize the technology.
Quick answers
What is Efferon NEO?
Efferon NEO is a pediatric blood purification device from Efferon. It received a CE mark in April, making it the first multimodal blood purification device specifically engineered for pediatric sepsis.
Where is Efferon NEO used?
The device is used in intensive care units across 30 countries, including hospitals in Europe, Saudi Arabia and Thailand.
What revenue target does Efferon have?
Efferon said it is on track to reach $2 million in annualized revenue by the end of 2026.